Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 18/20 | 0.63 |
| ▸ | EDNRB | P24530 | 16/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313203 | 0.87 | EDNRA (0.63) | EDNRAEDNRBKDM4ENPC1TP53 | |
| SCHEMBL6313421 | 0.86 | EDNRA (0.66) | EDNRAEDNRBKDM4ENPC1TP53 | |
| SCHEMBL7951239 | 0.80 | EDNRA (0.45) | EDNRAEDNRBKDM4ENPC1MAPT | |
| SCHEMBL4631355 | 0.77 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL7946892 | 0.77 | EDNRA (0.49) | EDNRAEDNRBKDM4ENPC1TP53 | |
| SCHEMBL7948219 | 0.76 | KDM4E (0.44) | EDNRAEDNRBKDM4ENPC1TP53 | |
| SCHEMBL6314152 | 0.76 | EDNRA (0.66) | EDNRAEDNRBKDM4ENPC1TP53 | |
| SCHEMBL7949358 | 0.75 | EDNRA (0.59) | EDNRAEDNRBKDM4ENPC1MAPT | |
| SCHEMBL7047200 | 0.75 | EDNRA (0.56) | EDNRAEDNRB | |
| SCHEMBL7949184 | 0.75 | EDNRA (0.50) | EDNRAEDNRBKDM4ENPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885KDM4E 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.